scholarly journals Early Dermoscopic Signs Leading to Primary Systemic Amyloidosis’ Diagnosis: A Case Report

2021 ◽  
pp. 2021023
Author(s):  
Trashita Hassanandani ◽  
Bhabani S.T.P. Singh ◽  
Bikash Ranjan Kar
Keyword(s):  
Case Report ◽  
Skin Lesions ◽  
Systemic Amyloidosis ◽  
Cutaneous Lesions ◽  
Protein Fibrils

Amyloidosis is primarily extracellular deposition of insoluble polymeric protein fibrils in tissues and organs. About 25 percent of patients with primary systemic amyloidosis have associated skin lesions in the form of papules, plaques or nodules. Dermoscopy of these skin lesions reveals characteristic glomerular vessels on a red to pink background. Here we present unique dermoscopic features of cutaneous lesions in a case of primary systemic amyloidosis.

scholarly journals Case Report: Mastocytosis: The Long Road to Diagnosis

2021 ◽  
Vol 12 ◽  
Author(s):  
Tiago Azenha Rama ◽  
Diana Martins ◽  
Nuno Gomes ◽  
Jorge Pinheiro ◽  
Ana Nogueira ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Case Report ◽  
Mast Cells ◽  
Allergic Sensitization ◽  
Skin Lesions ◽  
Normal Serum ◽  
Cutaneous Lesions ◽  
History Of ◽  
Exercise Induced ◽  
Low Prevalence

Mastocytosis is a heterogeneous group of disorders characterized by expansion and accumulation of clonal mast cells. Patients mainly present with either cutaneous lesions, anaphylaxis, or both. Its low prevalence and unusual features often hinder its diagnosis for several years. We report the case of an 18-year-old male who was referred to our department with a long-standing history of atypical skin lesions, allergic rhinitis, exercise-induced bronchoconstriction and what was believed to be food-related flushing and anaphylaxis, that was later diagnosed with mastocytosis. This case illustrates the need to consider investigating for mastocytosis when recurrent anaphylaxis is present, especially in the presence of atypical skin lesions, even if normal serum basal tryptase levels and allergic sensitization are present.

scholarly journals Isolation of Rhodotorula mucilaginosa from skin lesions in a Southern sea lion (Otaria flavescens): a case report

2010 ◽  
Vol 55 (No. 6) ◽  
pp. 297-301 ◽  
Author(s):  
S. Alvarez-Perez ◽  
A. Mateos ◽  
L. Dominguez ◽  
E. Martinez-Nevado ◽  
JL Blanco ◽  
...  
Keyword(s):  
Case Report ◽  
Topical Treatment ◽  
Skin Lesions ◽  
Rhodotorula Mucilaginosa ◽  
Sea Lion ◽  
Cutaneous Lesions ◽  
Repeat Testing ◽  
Otaria Flavescens ◽  
Clinical Recovery

This paper reports the isolation of Rhodotorula mucilaginosa from skin lesions in a Southern sea lion (Otaria flavescens). The microorganism was isolated from cutaneous lesions, identified by the commercial API 20 C AUX system, and confirmed by sequencing. Topical treatment with sertaconazol resulted in complete clinical recovery of the animal and repeat testing did not result in the recovery of the yeast from the healed lesion sites.

scholarly journals New-onset cutaneous sarcoidosis under tocilizumab treatment for giant cell arteritis: a quasi-paradoxical adverse drug reaction. Case report and literature review

2019 ◽  
Vol 11 ◽  
pp. 1759720X1984179 ◽  
Author(s):  
Rosaria Del Giorno ◽  
Alfonso Iodice ◽  
Cristina Mangas ◽  
Luca Gabutti
Keyword(s):  
Case Report ◽  
Clinical Response ◽  
Giant Cell Arteritis ◽  
Giant Cell ◽  
Case Reports ◽  
Skin Lesions ◽  
Cutaneous Sarcoidosis ◽  
Cutaneous Lesions ◽  
Topical Corticosteroids ◽  
New Onset

Background: New-onset sarcoidosis has been previously described in three case reports in patients affected by rheumatoid arthritis treated with tocilizumab (TCZ). The existence of a cause–effect mechanism between the biological treatment and the onset of the illness is still being debated. Patient concerns: A 74-year-old woman was diagnosed with giant cell arteritis (GCA). The first-line treatment with glucocorticoids; and the second-line with methotrexate and low-dose glucocorticoids were stopped due to multiple pathological vertebral fractures and insufficient biological and clinical response. The cytotoxic agent, cyclophosphamide, was then introduced and in turn stopped, because of gastrointestinal side effects. Thereafter a treatment with TCZ was begun. The patient experienced good clinical response; however, 8 months later she developed painful hyper-pigmented reddish cutaneous micronodular lesions localized to the abdomen and thorax. A cutaneous biopsy was performed, and histological analysis showed noncaseating epithelioid granulomas in the hypodermis. The diagnosis of cutaneous sarcoidosis was made. Interventions: Topical corticosteroids were administered and, as requested by the patient, TCZ was discontinued with slow but complete resolution of the skin lesions. After TCZ discontinuation however, the GCA flared and the patient’s symptoms and biological abnormalities reappeared. Thus, after a 6-month suspension, TCZ was re-administered. At 2 months later the skin lesions compatible with cutaneous sarcoidosis reappeared. Topical corticosteroids were once again prescribed and as suggested by the patient the TCZ posology was reduced. The patient’s symptoms disappeared, and the cutaneous lesions resolved. Lessons: The time elapsed from TCZ treatment start and the onset of cutaneous sarcoidosis, as well as its recurrence after TCZ suspension and rechallenge supported the diagnosis of a drug-induced reaction. To the best of our knowledge, this case report represents the first instance of cutaneous sarcoidosis most likely induced by TCZ in patients affected by GCA. In addition, our case emphasizes that although TCZ in monotherapy confirms to be an effective treatment for GCA, further immunological disorders could be unmasked, and the discussed side effect of the drug could be dose-dependent.

scholarly journals Cutaneous Sarcoidosis in a patient with left Hilar calcification of the lungs - A Case Report

2016 ◽  
Vol 8 (3) ◽  
pp. 161-170
Author(s):  
Mirjana Paravina ◽  
Milanka Ljubenović ◽  
Milenko Stanojević ◽  
Milica Stepanović ◽  
Dragica Marković
Keyword(s):  
Case Report ◽  
Lymph Nodes ◽  
Female Patient ◽  
Skin Lesions ◽  
Granulomatous Disease ◽  
Cutaneous Sarcoidosis ◽  
Cutaneous Lesions ◽  
Antimalarial Therapy ◽  
Cutaneous Granuloma ◽  
Systemic Manifestations

Abstract Sarcoidosis is an acquired idiopathic granulomatous disease, which is characterized by noncaseating epithelioid granulomas in organs and tissues. Most frequently it affects the lungs, liver, lymph nodes, skin, eyes and other organs. The cutaneous lesions appear in 20 - 30% of patients with systemic manifestations, and in 25% of them they appear without systemic manifestations. Based on the histopathological characteristics, cutaneous lesions are divided into specific, characterized by cutaneous granuloma, and non-specific, which are not granulomatous. Moreover, they can be classified as typical and atypical. We are presenting a female patient with unilateral hilar calcification of the lungs, who exhibited plaque skin lesions typical for sarcoidosis, with a specific granulomatous histology and a favorable response to corticosteroid and antimalarial therapy.

scholarly journals Cutaneous Side Effect of Hydroxurea in a Sickle Cell Anaemia Child-A Case Report

2019 ◽  
pp. 1-6
Author(s):  
A. O. Salako ◽  
S. O. Ogunmefun ◽  
O. W. Aworanti
Keyword(s):  
Case Report ◽  
Side Effects ◽  
Sickle Cell ◽  
Side Effect ◽  
Low Dose ◽  
Sickle Cell Anaemia ◽  
Skin Lesions ◽  
Cutaneous Lesions ◽  
Care Givers ◽  
Cutaneous Side Effect

Background: Hydroxyurea (HU) has redefined the quality of life of children with sickle cell anaemia and their care givers. Despite the acclaimed benefits of HU, the drug could be associated with variable side effects affecting different systems in the human body, including the skin and integuments. The aim of this report is to raise the awareness about the less common side effects of HU. Case Report: A 5-year 8 months old homozygous sickle cell anaemia child presented with pruritic hyperpigmented lesions on the trunk, arms and the legs, four weeks after commencement of HU. HU was initially discontinued for two weeks and thereafter recommenced with a different brand but there was worsening skin lesions despite at a daily low dose of 10 mg/kg. The rashes eventually resolved with low dose once in 3 days HU therapy.  She had recurrent episodes of acute painful crisis; average of three [3] episodes per year warranted hospital admission prior to commencement, but with HU therapy, there has been significant improvement in the crisis. Discussion: Cutaneous lesions are uncommon side effect of hydroxyurea. This side effect is dependent on genetic predisposition and photosensitivity. However, with the established benefit of HU in the management sickle cell anaemia, it is important for the sickle cell experts to continue to monitor closely the children for both the common and rare side effects and to individualize therapy to ensure maximal benefit with minimal or no side effects.

scholarly journals The Role of Atorvastatin in Management of Eruptive Xanthoma on a Boy: A Case Report

2021 ◽  
Vol 9 (C) ◽  
pp. 151-153
Author(s):  
Harapan Parlindungan Ringoringo
Keyword(s):  
Body Weight ◽  
Case Report ◽  
Clinical Presentation ◽  
Skin Lesions ◽  
Chief Complaint ◽  
Laboratory Examination ◽  
Cutaneous Lesions ◽  
Early Therapy ◽  
Intense Pruritus

Background: Eruptive xanthoma is a benign skin lesion caused by the accumulation of cholesterol and triglycerides in the skin's dermis. Xanthoma can be an early clinical manifestation of systemic diseases such as dyslipidemia, cardiovascular disease, diabetes mellitus. Clinical presentation varies from asymptomatic skin lesions to intense pruritus and tenderness. Aim: This study aims that oral atorvastatin is effective in treating a child with eruptive xanthoma. Case report: A three-year-old boy with an 8.4 kg body weight and 82.5 cm height came to the hospital with the chief complaint of small yellowish-white papules and nodes, discrete, 2-5 mm in size, painless on pressing, itchy, scattered, mainly in the lower extremity around the buttocks. On laboratory examination, Hb 11.5 g/dL, leukocyte 9,900/ul, platelet 413,000/uL, blood glucose 66 mg/dL. Further evaluation revealed total cholesterol 814 mg/dL, LDL 970 mg/dL, HDL 341 mg/dl, triglycerides 621 mg/dL; there is no evidence of familial hypercholesterolemia. The diagnosis is eruptive xanthoma.  After starting treatment with atorvastatin 0.2 mg/kg body weight/day in one dose for six months, his cutaneous lesions gradually subsided and significantly decreased cholesterol, LDL, HDL, and triglyceride levels. Conclusion: Early therapy with atorvastatin will reduce the morbidity and mortality of eruptive xanthoma.

scholarly journals Disseminated cutaneous sporotrichosis in a patient with AIDS: report of a case

2002 ◽  
Vol 35 (6) ◽  
pp. 655-659 ◽  
Author(s):  
Miriam Tomoko Mitsuno Carvalho ◽  
Adriana Pinheiro de Castro ◽  
Cristiane Baby ◽  
Betina Werner ◽  
José Filus Neto ◽  
...  
Keyword(s):  
Case Report ◽  
Male Patient ◽  
Sporothrix Schenckii ◽  
Skin Lesions ◽  
Response To Therapy ◽  
Initial Presentation ◽  
Hiv Positive ◽  
Cutaneous Lesions ◽  
The Face

We describe a case report of disseminated cutaneous sporotrichosis as the initial presentation of AIDS in a 24-year-old HIV-positive male patient. He presented multiple ulcerated skin lesions distributed over the face, thorax, legs and arms. Biopsy of one of the cutaneous lesions was suggestive of sporotrichosis and culture isolated Sporothrix schenckii. Itraconazole was started and the lesions progressively resolved after 15 days of medication. The patient was discharged with this medication but he did not return for follow-up. He died three months later in another hospital. Therapy of sporotrichosis in HIV-infected patients remains unclear and the response to therapy is variable. Itraconazole is highly concentrated in the skin and is one of the options for treatment of disseminated sporotrichosis.

scholarly journals Cutaneous manifestations of COVID-19 in Mexican patients: A case series and review of literature

2021 ◽  
Vol 9 ◽  
pp. 2050313X2199719
Author(s):  
Juan Carlos Palomo-Pérez ◽  
Maria Elisa Vega-Memije ◽  
David Aguilar-Blancas ◽  
Erik González-Martínez ◽  
Lucia Rangel-Gamboa
Keyword(s):  
Respiratory Symptoms ◽  
Case Series ◽  
Signs And Symptoms ◽  
Skin Lesions ◽  
World Health ◽  
Medical Community ◽  
Atypical Pneumonia ◽  
Cutaneous Lesions ◽  
Cutaneous Manifestations ◽  
Mexican Patients

China officially recognized atypical pneumonia outbreak in December 2019; on 11 March 2020, the World Health Organization declared COVID-19 as a pandemic that is produced by a new coronavirus, named SARS-CoV-2, of rapid transmissibility, which can be asymptomatic, with mild to severe respiratory symptoms, and with cardiovascular, neurological, gastrointestinal, and cutaneous complications. Considering that the pandemic prolonged more than initially expected was prognostic, it is essential for the medical community to identify the signs and symptoms of COVID-19. Thus, this work’s objectives were to present cases of cutaneous lesions observed in COVID-19 Mexican patients. We register cutaneous lesions in COVID-19 patients referred from internal medicine and otorhinolaryngology services to dermatology. We presented four interesting cases with cutaneous lesions, including exanthema morbilliform, urticaria, chilblains, ecchymosis, and facial edema, and review the available literature. The most frequent cutaneous markers are rash, chilblains, and urticaria. Skin lesions may be the first manifestation of COVID-19, accompany initial respiratory symptoms, or appear during the disease course. Symptoms associated with vascular changes (livedo reticularis and vasculitis) are considered of poor prognosis.

Photosensitization Induced by Heterophyllaea pustulata in Goats: Sequential Development of Skin Lesions

2021 ◽  
Vol 58 (3) ◽  
pp. 568-573
Author(s):  
Juan F. Micheloud ◽  
Lluís Luján ◽  
Luis A. Colque-Caro ◽  
Susana C. Núñez-Montoya ◽  
Claudio G. Barbeito ◽  
...  
Keyword(s):  
Cell Death ◽  
Oral Dose ◽  
Skin Lesions ◽  
Crust Formation ◽  
Cutaneous Lesions ◽  
Protein Ratio ◽  
Dermal Fibrosis ◽  
Sequential Development ◽  
Treatment Changes ◽  
Skin Biopsies

Five adult Saanen goats received a single oral dose of Heterophyllaea pustulata containing 42.25 μg/kg rubiadin (anthraquinone) and 3 adult goats were untreated controls. All goats were exposed to sunlight and sequential ear skin biopsies were collected before treatment and at 32 hours, 3 days, 8 days, and 15 days after treatment. Changes at 32 hours after dosing included epidermal spongiosis, single cell death and acantholysis, an increased BAX/BCL-2 protein ratio, and dermal edema. Lesions at day 3 included epidermal and adnexal necrosis, crust formation, and acanthosis. Acanthosis, hyperkeratosis, and dermal fibrosis and neovascularization were present at day 15. The pro-apoptotic (BAX)/anti-apoptotic (BCL-2) protein ratio increased at 32 hours, whereas epidermal and dermal PCNA immunolabeling increased between days 8 and 15 after treatment. The cutaneous lesions were consistent with sunlight-induced damage, and the occurrence in treated but not control goats indicates photosensitization.

Sign in / Sign up

Export Citation Format

Share Document